Hosted in Canada, but is it Sovereign?

Data sovereignty is making headlines in Canada this fall. On October 29, the federal government announced an equity investment of up to $1.6 billion in a Canadian AI company, framing it as a sovereignty issue: who controls sensitive data, where it resides, and how it may be used.

These are the same questions life sciences organizations face with every cloud system. Patient data, clinical trial results, proprietary R&D and manufacturing records are among the most sensitive information a business can hold. Building on the data sovereignty webinar InnovX co-presented in October, this article explains why “hosted in Canada” is not enough, and how sovereignty can be managed within the system lifecycle that GxP teams already follow.

Residency, Control, Sovereignty: What Is the Difference?

“Hosted in Canada” is not enough on its own, because three different questions are often confused:

Data residency: Where is your data physically stored, backed up, and processed?

Operational control: Who administers, supports, and can access the environment, including remote support teams and subcontractors?

Data sovereignty: Whose laws can compel access to the data?

Data stored in a Canadian data centre is not automatically sovereign. Under the U.S. CLOUD Act, adopted in 2018, U.S. authorities can use legal process to require service providers subject to U.S. jurisdiction to disclose data in their possession, custody, or control, wherever that data is stored. What matters is who controls the data, not only where the servers are.

Quebec privacy law adds its own layer. The private-sector privacy law modernized by Law 25 requires a business to conduct a privacy impact assessment before communicating personal information outside Quebec, including to another Canadian province.

This obligation applies to personal information, which is not limited to patient files: clinical and quality records can also contain it. For data that is not personal information, such as formulations or process know-how, sovereignty is mainly a question of intellectual property protection, confidentiality, and business risk.

Where Does Sovereignty Fit in Your GxP Lifecycle?

GxP regulations such as 21 CFR Part 11 and EU GMP Annex 11 do not specify where data must be hosted, and data residency is not itself a GxP requirement. They do require that records remain accessible, protected and under the regulated company’s control, and that supplier responsibilities be formally defined. Personal-data rules (e.g., GDPR, Quebec Law 25) apply independently and may impose conditions on cross-border transfers. Outsourcing the infrastructure does not outsource this responsibility. The overlap between sovereignty and GxP lies in operational control. Who can administer the system, how that access is restricted, and whether changes are traceable are core data integrity and security concerns. Legal jurisdiction, by contrast, is mainly a confidentiality and legal risk. Both belong in your assessment, but they are addressed with different tools.

In practice, sovereignty does not need a separate process. It fits into the lifecycle you already run: documented in your requirements, assessed during risk and supplier assessments, secured in the contract and quality agreement, verified during qualification where it can be tested, and monitored through periodic review.

How Do You Address Sovereignty in Practice?

Sovereignty is not something you buy with a product. It results from how a system is selected, configured, contracted, and overseen. A practical approach has five steps:

1.     Identify critical data and systems: patient and clinical data, proprietary R&D, and GxP records.

2.     Assess sovereignty risks: data location, administrative access, foreign support, backups, and subcontractors.

3.     Define requirements: document your sovereignty expectations in your user requirements, alongside security, continuity, and auditability.

4.     Select and contract: choose an architecture and access model that meets those requirements, and secure commitments on data location, access, and subcontracting in the contract and quality agreement.

5.     Verify and monitor: verify testable controls during qualification, such as the configured hosting region and administrator access, then monitor them through periodic access reviews and supplier oversight.

During supplier assessment, four questions quickly separate sovereign claims from sovereign operations:

• Who operates and administers the environment, and from which countries?

• Where are backups and replicas stored, and can data leave the territory without your consent?

• Who owns the technology used to store or process the data (infrastructure, networking, databases and processing layers), and which foreign laws apply to it?

• Which subcontractors have access to the environment?

Independent assurance, such as a SOC 2 Type II report or ISO 27001 certification, is useful evidence of security controls, but it does not answer the jurisdiction question on its own. Document the answers and the rationale behind your decision. In an audit, a reasoned, documented decision is far easier to defend than the assumption that “the data is in Canada, so we are covered.”

Making Sovereignty a Deliberate Choice

As cloud adoption and AI use grow, partners, auditors, and authorities are increasingly likely to ask who controls your data. Organizations that address sovereignty from the start of a system’s lifecycle are better placed to answer with confidence.

As a tech-agnostic firm, InnovX helps life sciences organizations define these requirements, assess cloud suppliers against them, and validate the systems they choose. Because sovereignty also has a legal dimension, we recommend involving legal counsel in your assessment.

Handled this way, data sovereignty is no longer just a constraint. It becomes a deliberate choice that supports innovation while keeping you in control of your data.